Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Translational Pharmacology

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1665174

This article is part of the Research TopicEmerging Targeted and Immunotherapeutic Strategies in Oncology: From Solid Tumors to Hematologic MalignanciesView all 3 articles

Global Research Trends on ALK-TKIs in Non-Small Cell Lung Cancer: A Bibliometric Analysis

Provisionally accepted
Yafeng  LiuYafeng LiuZhaojin  HanZhaojin HanYujia  LiYujia LiPengfei  ZhangPengfei ZhangQiushi  WangQiushi Wang*
  • Department of Thoracic Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China

The final, formatted version of the article will be published soon.

Background: Lung cancer remains the leading cause of cancer-related incidence and mortality worldwide. Non-small cell lung cancer (NSCLC) constitutes the most prevalent histological subtype of lung cancer. A notable proportion of NSCLC patients harbor mutations in the anaplastic lymphoma kinase (ALK) gene, and treatment with ALK-TKIs has demonstrated favorable therapeutic efficacy in ALKpositive patients. This study aimed to systematically analyze the body of literature on ALK-TKIs in NSCLC over the past decade from a bibliometric perspective. Methods: Relevant literature on anaplastic ALK-TKIs for the treatment of NSCLC published between 2015 and 2024 was retrieved from the Web of Science Core Collection. Only English-language publications categorized as original researches and reviews were included. Additionally, clinical trial data from the past decade were collected from the ClinicalTrials.gov database. Bibliometric analysis, data processing, and visualization were conducted using CiteSpace, VOSviewer, Excel, and R. Results: Between 2015 and 2024, a total of 2,877 publications on ALK-TKIs for NSCLC were identified, with the annual output remaining consistently high, and 198 clinical trials were registered on ClinicalTrials.gov. China contributed the highest number of publications, while Massachusetts General Hospital emerged as the most prolific institution. The most influential journal in this field was Lung Cancer, and Alice T. Shaw was both the most prolific and one of the most influential authors. Keywords such as 'lorlatinib', 'resistance', 'circulating tumor DNA', and 'immunotherapy', along with keyword clustering, indicate current research hotspots and future directions in this field.This study provides a comprehensive bibliometric analysis and summary of the developmental trajectory, current research landscape, and future trends in ALK-TKI therapy for NSCLC over the past decade, with individualized and precision medicine remaining the primary direction for the development of ALK-TKI therapy in NSCLC.

Keywords: NSCLC, ALK mutation, ALK-TKIs, bibliometric analysis, Citespace, VOSviewer

Received: 13 Jul 2025; Accepted: 04 Aug 2025.

Copyright: © 2025 Liu, Han, Li, Zhang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Qiushi Wang, Department of Thoracic Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.